13 Grants
2023
Polyesters with controlled topologies for probing transcytosis at the gut-blood barrier
Majeti, Ravikumar N⋅Shah, Dhaval K and Shah, Dhaval K
National Institutes of Health (NIH), National Institute of General Medical Sciences (NIGMS) (ID: 1R01GM146097-01A1), $328,441USD, 2023-09-15 -- 2027-06-30
2021
Engineering the next generation nanoparticle-cyclosporine A therapy in lupus
ARORA, MEENAKSHI and MAJETI, RAVIKUMAR N
National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) (ID: 5R01AI155908-03), $467,374USD, 2020-09-21 -- 2025-08-31
 
Oral delivery of insulin using ligand-directed nanoparticles that do not compete with physiological ligands
GANUGULA, RAGHU and MAJETI, RAVIKUMAR N
National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (ID: 7R01DK125372-02), $372,500USD, 2020-07-01 -- 2024-03-31
 
Systemic anti-inflammatory therapy to prevent or delay diabetic cataracts and treat post-surgical inflammation
MAJETI, RAVIKUMAR N
National Institutes of Health (NIH), National Eye Institute (NEI) (ID: 5R01EY028169-06), $360,163USD, 2017-09-30 -- 2022-08-31
 
Urolithin A nanoparticle therapy for acute kidney injury
ARORA, MEENAKSHI and MAJETI, RAVIKUMAR N
National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (ID: 1R01DK128597-01), $323,152USD, 2021-05-01 -- 2026-03-31
2020
Engineering the next generation nanoparticle-cyclosporine A therapy in lupus
ARORA, MEENAKSHI and MAJETI, RAVIKUMAR N
National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) (ID: 7R01AI155908-02), $488,039USD, 2020-09-21 -- 2025-08-31
 
Engineering the next generation nanoparticle-cyclosporine A therapy in lupus
ARORA, MEENAKSHI and MAJETI, RAVIKUMAR N
National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) (ID: 1R01AI155908-01), $569,146USD, 2020-09-21 -- 2025-08-31
 
Oral delivery of insulin using ligand-directed nanoparticles that do not compete with physiological ligands
GANUGULA, RAGHU and MAJETI, RAVIKUMAR N
National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (ID: 1R01DK125372-01), $378,125USD, 2020-07-01 -- 2024-03-31
 
Systemic anti-inflammatory therapy to prevent or delay diabetic cataracts and treat post-surgical inflammation
MAJETI, RAVIKUMAR N
National Institutes of Health (NIH), National Eye Institute (NEI) (ID: 5R01EY028169-04), $371,250USD, 2017-09-30 -- 2022-08-31
 
Systemic anti-inflammatory therapy to prevent or delay diabetic cataracts and treat post-surgical inflammation
MAJETI, RAVIKUMAR N
National Institutes of Health (NIH), National Eye Institute (NEI) (ID: 7R01EY028169-05), $371,250USD, 2017-09-30 -- 2022-08-31
2019
Systemic anti-inflammatory therapy to prevent or delay diabetic cataracts and treat post-surgical inflammation
MAJETI, RAVIKUMAR N
National Institutes of Health (NIH), National Eye Institute (NEI) (ID: 5R01EY028169-03), $371,250USD, 2017-09-30 -- 2022-08-31
2018
Systemic anti-inflammatory therapy to prevent or delay diabetic cataracts and treat post-surgical inflammation
MAJETI, RAVIKUMAR N
National Institutes of Health (NIH), National Eye Institute (NEI) (ID: 5R01EY028169-02), $371,250USD, 2017-09-30 -- 2022-08-31
2017
Systemic anti-inflammatory therapy to prevent or delay diabetic cataracts and treat post-surgical inflammation
MAJETI, RAVIKUMAR N
National Institutes of Health (NIH), National Eye Institute (NEI) (ID: 1R01EY028169-01), $371,250USD, 2017-09-30 -- 2022-08-31